Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 0.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

Malta - English - Medicines Authority

glaxo wellcome uk limited - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

actelion registration ltd - epoprostenol - pdr for soln for infusion - 0.5 milligram - epoprostenol

Ireland - English - HPRA (Health Products Regulatory Authority)

actelion registration ltd - epoprostenol - pdr for soln for infusion - 1.5 milligram - epoprostenol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 1.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph10.5) for solution for infusion vials (sandoz ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ph12) for solution for infusion vials (glaxosmithkline uk ltd - epoprostenol sodium - powder and solvent for solution for infusion - 1.5mg